Abstract
Anti-RA33 Antibodies are Present in a Subset of Patients with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Highlights
Patients with inflammatory arthritis (IA) associated with immune checkpoint inhibitor (ICI) treatment for cancer are typically seronegative for anti-CCP antibodies and rheumatoid factor, but little is known about the presence of other autoantibodies described in early inflammatory arthritis in this patient population
Anti-RA33 antibodies were found in 9/79 (11.4%) patients with ICI-induced IA but in 0/35 patients treated with ICIs who did not develop IA (0%; p=0.04)
We found no statistically significant differences in other clinical characteristics in those with and without anti-RA33 antibodies, but we observed trends toward anti-RA33 antibodies being more common in women and those receiving prior radiation therapy
Summary
We aimed to test whether patients with ICI-induced IA had antibodies to RA33 and whether anti-RA33 antibodies were specific to ICI-treated patients who did versus did not develop IA as an irAE
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
